ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.102,15
0,75%
S&P 500
5.930,85
1,09%
US Dollar vs BRL
6,086
-1,08%
Bitcoin
97.659,90
0,19%
Brent Oil
72,72
0,46%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Mainz BioMed NV (MYNZ)

  7. Mainz BioMed NV (MYNZ) Notícias

MYNZ

Mainz BioMed NV (MYNZ)

Mainz BioMed NV
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MYNZ
DataHoraFonteTítuloCódigoCompanhia
19/12/202410:01GlobeNewswire Inc.Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening TestNASDAQ:MYNZMainz BioMed NV
16/12/202419:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
16/12/202419:00GlobeNewswire Inc.Mainz Biomed Announces Closing of $8.0 Million Follow-On OfferingNASDAQ:MYNZMainz BioMed NV
16/12/202410:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MYNZMainz BioMed NV
13/12/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MYNZMainz BioMed NV
12/12/202422:00GlobeNewswire Inc.Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq RulesNASDAQ:MYNZMainz BioMed NV
11/12/202411:22InvestorsHub NewsWireSilexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXNNASDAQ:MYNZMainz BioMed NV
11/12/202410:00Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:MYNZMainz BioMed NV
29/11/202410:45GlobeNewswire Inc.Mainz Biomed Announces Stock SplitNASDAQ:MYNZMainz BioMed NV
12/11/202411:00GlobeNewswire Inc.Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global MarketsNASDAQ:MYNZMainz BioMed NV
05/11/202410:00Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:MYNZMainz BioMed NV
21/10/202409:01GlobeNewswire Inc.Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:MYNZMainz BioMed NV
08/10/202409:01GlobeNewswire Inc.Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New VersionNASDAQ:MYNZMainz BioMed NV
01/10/202409:01GlobeNewswire Inc.Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025NASDAQ:MYNZMainz BioMed NV
18/09/202409:01GlobeNewswire Inc.Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand AmbassadorNASDAQ:MYNZMainz BioMed NV
04/09/202405:01GlobeNewswire Inc.Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlertNASDAQ:MYNZMainz BioMed NV
25/07/202409:01GlobeNewswire Inc.Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User ConvenienceNASDAQ:MYNZMainz BioMed NV
09/07/202410:30AllPennyStocks.comMicro Cap Bid Up Following FDA Submission AnnouncementNASDAQ:MYNZMainz BioMed NV
09/07/202404:01GlobeNewswire Inc.Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening TestNASDAQ:MYNZMainz BioMed NV
02/07/202409:01GlobeNewswire Inc.Mainz Biomed Provides Half Year 2024 Corporate UpdateNASDAQ:MYNZMainz BioMed NV
03/06/202409:01GlobeNewswire Inc.Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024NASDAQ:MYNZMainz BioMed NV
31/05/202418:01GlobeNewswire Inc.Mainz Biomed Reports Results of 2024 Annual General MeetingNASDAQ:MYNZMainz BioMed NV
28/05/202409:01GlobeNewswire Inc.Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual MeetingNASDAQ:MYNZMainz BioMed NV
20/05/202409:01GlobeNewswire Inc.Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA TrialNASDAQ:MYNZMainz BioMed NV
10/05/202418:20Edgar (US Regulatory)Form D/A - Notice of Exempt Offering of Securities: [Amend]NASDAQ:MYNZMainz BioMed NV
07/05/202409:01GlobeNewswire Inc.Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.NASDAQ:MYNZMainz BioMed NV
25/04/202410:29GlobeNewswire Inc.Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer DiagnosticNASDAQ:MYNZMainz BioMed NV
09/04/202409:01GlobeNewswire Inc.Mainz Biomed Reports Full Year 2023 Financial ResultsNASDAQ:MYNZMainz BioMed NV
19/03/202409:01GlobeNewswire Inc.Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer TreatmentNASDAQ:MYNZMainz BioMed NV
18/03/202409:01GlobeNewswire Inc.Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic OptionsNASDAQ:MYNZMainz BioMed NV
 Apresentando as notícias mais relevantes sobre:NASDAQ:MYNZ

Seu Histórico Recente

LATK
MTRUSDT
MEGATRON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados